ANIP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
266.0M
+12.0%
237.5M
-3.9%
247.1M
+8.4%
227.8M
+7.8%
211.4M
Cost of Revenue
100.2M
+7.0%
93.6M
-6.7%
100.3M
+7.4%
93.4M
+25.2%
74.6M
Gross Profit
165.9M
+15.3%
143.9M
-2.0%
146.8M
+9.2%
134.4M
-1.7%
136.8M
Operating Expenses
125.4M
+19.5%
105.0M
-6.2%
111.9M
+14.4%
97.9M
-20.3%
122.9M
R&D
14.7M
+39.1%
10.6M
-13.5%
12.3M
-0.3%
12.3M
-25.6%
16.5M
SG&A
91.7M
+24.4%
73.7M
-11.0%
82.8M
+8.0%
76.7M
-6.3%
81.8M
Operating Income
40.5M
+4.0%
38.9M
+11.6%
34.9M
-4.6%
36.5M
+163.0%
13.9M
EBITDA
60.1M
+0.5%
59.8M
+4.1%
57.5M
-4.1%
59.9M
+61.2%
37.2M
Net Income
24.7M
-16.2%
29.5M
+7.3%
27.5M
+3.3%
26.6M
+211.3%
8.5M
EPS (Basic)
$1.09
-16.8%
$1.31
+6.5%
$1.23
+3.4%
$1.19
+221.6%
$0.37
EPS (Diluted)
$1.05
-18.0%
$1.28
+18.5%
$1.08
-4.4%
$1.13
+213.9%
$0.36
Shares (Diluted)
21.9M
+1.7%
21.5M
-8.2%
23.5M
+11.2%
21.1M
+3.9%
20.3M
ANI Pharmaceuticals (ANIP) โ€” Financials